Renasant Bank Sells 925 Shares of Eli Lilly and Company $LLY

Renasant Bank lowered its position in Eli Lilly and Company (NYSE:LLY) by 69.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 405 shares of the company’s stock after selling 925 shares during the period. Renasant Bank’s holdings in Eli Lilly and Company were worth $316,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Maple Capital Management Inc. increased its stake in Eli Lilly and Company by 1.5% in the 2nd quarter. Maple Capital Management Inc. now owns 46,767 shares of the company’s stock valued at $36,456,000 after buying an additional 678 shares during the last quarter. Accredited Investors Inc. boosted its stake in shares of Eli Lilly and Company by 17.1% in the 2nd quarter. Accredited Investors Inc. now owns 3,851 shares of the company’s stock worth $3,002,000 after buying an additional 561 shares during the last quarter. United Asset Strategies Inc. grew its holdings in shares of Eli Lilly and Company by 2.3% in the second quarter. United Asset Strategies Inc. now owns 4,275 shares of the company’s stock valued at $3,332,000 after acquiring an additional 98 shares in the last quarter. National Mutual Insurance Federation of Agricultural Cooperatives grew its holdings in shares of Eli Lilly and Company by 20.1% in the second quarter. National Mutual Insurance Federation of Agricultural Cooperatives now owns 41,800 shares of the company’s stock valued at $32,584,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Wealth Alliance LLC increased its position in shares of Eli Lilly and Company by 10.9% during the second quarter. Wealth Alliance LLC now owns 8,382 shares of the company’s stock valued at $6,534,000 after acquiring an additional 824 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $987.48 on Wednesday. The firm has a market cap of $933.55 billion, a P/E ratio of 64.54, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company’s 50 day moving average is $809.69 and its 200-day moving average is $776.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $999.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LLY. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Finally, BMO Capital Markets increased their price objective on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $981.89.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.